Genome Therapeutics Changes Name to Oscient Pharmaceuticals Corporation to Reflect Focus on Drug Development and Commercializati
"As we prepare for the launch of FACTIVE(R) tablets, we believe it is important for our new company name to more accurately reflect our mission and strategy," stated Steven M. Rauscher, President and CEO of Oscient Pharmaceuticals. "The name Oscient Pharmaceuticals, with its strong root in pharmaceutical science, reflects our continued commitment to the commercialization and clinical development of our pipeline."
At the Company's Annual Meeting held today in Boston, shareholders approved all five proposals presented for vote. Oscient's corporate headquarters will remain in Waltham, Massachusetts, with west coast offices in South San Francisco.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.